For the second quarter of 2026, analysts expect Structure Therapeutics to report a net loss of $0.39 per share on zero revenue, while the current stock price of $48.04 remains significantly below the $110.55 consensus price target.
Investors are laser-focused on the definitive timeline for initiating the Phase 3 registrational program for aleniglipron (GSBR-1290), the company’s lead oral GLP-1 candidate for obesity.
This late-stage trial is anticipated to begin in the third quarter of 2026 following successful Phase 2b results and positive regulatory feedback from the FDA. Management's update on the $1.5 billion cash runway and the progress of the oral amylin candidate, ACCG-2671, will be critical for assessing clinical momentum through 2028.